UK start-up George Medicines has named Mark Mallon as its new chief executive, who will oversee the company as it tries to get its triple therapy for high blood pressure o
Ironwood Pharma has issued an upbeat assessment of phase 3 trial data with apraglutide for short bowel syndrome (SBS), but missed secondary outcome measures led to a sharp
Gastrointestinal disease specialist Ironwood Pharma has agreed a $1 billion deal to buy VectivBio and its drug candidate for short bowel syndrome (SBS), betting on positiv